Brainstorm Cell Therapeutics | BCLI - Cash And Equivalent


Brainstorm Cell Therapeutics reported $22K in Cash and Equivalent for its fiscal quarter ending in June of 2026.





Cash And Equivalent Change Date
Alterity Therapeutics Limited AUD 15.77M 9.56M Jun/2023
Biogen USD 1.3B 18.9M Sep/2026
Brainstorm Cell Therapeutics USD 22K 7K Jun/2026
Cipla INR 16.59B 6.41B Sep/2026
Clal Biotechnology ILS 5.73M 1.71M Dec/2023
Compugen USD 10.28M 2.15M Jun/2026
CSL USD 2.16B 633M Jun/2025
Cytokinetics USD 203.43M 51.84M Sep/2026
Gilead Sciences USD 3.18B 4.45B Jun/2026
Grifols EUR 979.78M 334.84M Dec/2024
Halozyme Therapeutics USD 1.03B 866.85M Sep/2026
Mesoblast USD 129.57M 31.58M Dec/2025